AndroGel Cost in Idaho 2026: Cash Price, Insurance, Medicaid & Compounded Alternatives

What Does AndroGel Cost in Idaho in 2026?

At Idaho retail pharmacies, AndroGel's cash price sits at approximately $510 per month in 2026, matching the AbbVie manufacturer list price. That figure applies to the branded 1.62% formulation dispensed as a metered-dose pump. Generic testosterone gel 1.62% (actavis/generic) is available at some Idaho chains for $180 to $240 per month depending on the pharmacy and whether a discount card is applied.

Cash prices vary by pharmacy. A 30-day supply of AndroGel 1.62% (75 g pump) quoted at several Idaho locations in early 2026 ranged from $480 at independent pharmacies using GoodRx to $535 at major chains without a coupon. Applying a free GoodRx or RxSaver coupon code at checkout can cut that figure to as low as $170 to $200 for the generic equivalent at Walmart, Fred Meyer, or Albertsons pharmacies in Boise, Idaho Falls, and Twin Falls.

The branded product's cost has risen roughly 4 to 6 percent annually since its FDA approval. The FDA approved AndroGel 1% in 2000 and the higher-concentration 1.62% formulation in 2011; both remain on the market see FDA label.

Why the Branded Price Is So High

AbbVie holds the AndroGel patent estate and sets the wholesale acquisition cost. Pharmacy benefit managers negotiate rebates that rarely reach cash-pay patients. Patients without insurance or with high-deductible plans bear the full WAC. Generic competition has driven costs down for some formulations, but the branded 1.62% pump still commands a premium at most Idaho retail locations.

Does Idaho Medicaid Cover AndroGel?

Idaho Medicaid does not cover AndroGel or other brand-name testosterone gels for male hypogonadism in 2026. The Idaho Department of Health and Welfare's Preferred Drug List excludes branded topical testosterone products from the outpatient pharmacy benefit for adult males. Generic testosterone gel is also not a covered benefit for this indication under standard Idaho Medicaid managed care contracts as of the current review date.

Patients enrolled in Idaho Medicaid who have documented hypogonadism should ask their prescriber to submit a prior authorization request citing the specific ICD-10 code (E29.1, testicular hypofunction). Prior authorizations for testosterone replacement have occasionally been approved on a case-by-case basis when a patient demonstrates a clear medical necessity beyond primary hypogonadism, such as Klinefelter syndrome or pituitary disease. Approval is not guaranteed and denial rates remain high for this drug class in Idaho.

For Idaho Medicaid members, injectable testosterone cypionate 200 mg/mL (a covered generic) is typically the preferred cost-effective route, with a dispensed cost well under $30 per month. Discussing a formulation switch with your prescriber may resolve the coverage gap entirely if you are primarily concerned about cost rather than delivery method.

Is Compounded Testosterone Gel Legal in Idaho?

Yes. Compounded testosterone gel is legally available in Idaho through state-licensed 503A compounding pharmacies. The term "503A" refers to Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional patient-specific compounding by licensed pharmacists see FDA 503A overview. A valid, patient-specific prescription from a licensed Idaho prescriber is required; testosterone is a Schedule III controlled substance under the DEA, so both the prescriber and dispensing pharmacy must comply with federal and Idaho controlled substance regulations.

The HealthRX clinical team uses the following decision framework when advising Idaho patients choosing between branded AndroGel and compounded testosterone gel:

Step 1, Confirm the diagnosis. Serum total testosterone should be measured on two separate mornings (before 10 a.m.) and fall below 300 ng/dL on both draws, paired with symptoms consistent with hypogonadism. The Endocrine Society's 2018 Clinical Practice Guideline recommends this two-sample confirmation before initiating therapy see Endocrine Society guideline.

Step 2, Check insurance first. If a commercial plan covers AndroGel or a generic testosterone gel with a low copay, the branded or generic product may cost less than a compounded alternative after the AbbVie savings card is applied.

Step 3, Price the compounded option. If the net cost still exceeds $120 per month, a 503A pharmacy compound (typically testosterone 1.62% or 2% gel in a customizable base) at $120 per month is a clinically reasonable alternative.

Step 4, Verify the pharmacy's credentials. Idaho patients should confirm the compounding pharmacy holds an active Idaho Board of Pharmacy license. The National Association of Boards of Pharmacy (NABP) Verified Pharmacy Program can confirm legitimacy.

Step 5, Monitor equivalently. Compounded testosterone gel should be monitored with the same serum testosterone targets (400 to 700 ng/dL mid-cycle) as branded AndroGel. Formulation differences in penetration enhancers may alter absorption; a follow-up testosterone level 4 to 6 weeks after switching is advisable.

At approximately $120 per month versus $510, the compounded route saves Idaho cash-pay patients roughly $4,680 per year. Absorption profiles between branded and compounded gels can differ, so clinical monitoring matters more than the product name.

Which Insurance Plans Cover AndroGel in Idaho?

Coverage depends on your specific plan's pharmacy formulary. Here is how the major payer categories typically handle AndroGel in Idaho:

Commercial plans (Blue Cross of Idaho, Regence BlueShield of Idaho, PacificSource, SelectHealth). Most commercial formularies place branded AndroGel on Tier 3 (non-preferred brand), which generates a copay of $60 to $120 per fill after the deductible is met. Generic testosterone gel is usually placed on Tier 2 (preferred brand or generic), cutting cost to $30 to $60 per fill at many plans. Always call the pharmacy benefits number on your insurance card to verify your plan's current tier before filling.

Employer self-insured plans. Benefit designs vary widely. Some large Idaho employers (healthcare systems, state government) carve out testosterone products entirely or require step therapy through injectable testosterone first. Confirm with your HR benefits administrator.

Medicare Part D. Medicare Part D plans vary by formulary. CMS data shows that roughly 60 percent of Part D plans covered some form of testosterone gel in 2025, typically at Tier 3 or Tier 4. Premium support programs do not cover brand AndroGel at the $0 level for most Medicare beneficiaries. Check the Medicare Plan Finder at medicare.gov for your specific plan's 2026 formulary.

Idaho Medicaid. As described above, not covered for male hypogonadism.

VA and TRICARE. Veterans receiving care through the Boise VA Medical Center may access testosterone products through the VA national formulary; testosterone gel is on the VA National Formulary as a non-formulary item requiring justification in most cases, with injectable testosterone cypionate preferred. TRICARE covers testosterone gel under the pharmacy benefit with applicable cost-shares.

How the AbbVie Savings Card Works in Idaho

AbbVie offers the myAbbVie Assist program, which includes a copay savings card for commercially insured patients and a patient assistance program (PAP) for uninsured patients who meet income eligibility thresholds.

For commercially insured Idaho patients, the AndroGel copay card can reduce the monthly out-of-pocket cost to as low as $0, depending on the plan and the calendar year maximum benefit (AbbVie caps the total program benefit). The card does not apply to patients covered by federal programs including Medicare, Medicaid, TRICARE, or the VA.

For uninsured or underinsured Idaho patients below 400 percent of the federal poverty level, the AbbVie myAbbVie Assist PAP can provide AndroGel at no cost. Applications require proof of income, proof of residency, and a completed prescriber attestation form. Processing typically takes 3 to 4 weeks for the first shipment, so patients should not delay applying while waiting on other coverage determinations.

To enroll, visit abbvie.com/myabbvieassist or call AbbVie patient support directly. Idaho prescribers can also initiate the enrollment on the patient's behalf through the portal.

Clinical Evidence Supporting Testosterone Gel Therapy

The scientific foundation for testosterone replacement therapy using gel formulations is well-established in men with confirmed hypogonadism. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in 788 men aged 65 and older with low testosterone (below 275 ng/dL), found that testosterone gel (targeting levels of 500 to 999 ng/dL) improved sexual function scores significantly compared with placebo over 12 months [1]. Bone mineral density also increased in the testosterone-treated arm of the bone trial component.

The TTrials authors noted: "Testosterone treatment increased sexual activity, sexual desire, and erectile function," while also observing mixed results across the cognitive and physical domains [1]. These nuanced findings underscore why testosterone therapy is appropriate for symptomatic hypogonadism rather than age-related decline alone.

The Endocrine Society's 2018 guideline states: "We suggest against making a diagnosis of androgen deficiency in men with acute or subacute illness and recommend treatment of hypogonadal men with testosterone to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density" see Endocrine Society guideline.

For topical gel specifically, the FDA-approved labeling for AndroGel 1.62% specifies a starting dose of 40.5 mg applied once daily to the shoulders or upper arms, with dose adjustments based on serum testosterone levels drawn at day 14 and day 28 see FDA label. Target serum testosterone should fall within the normal range (approximately 300 to 1 to 000 ng/dL per most laboratory reference intervals), with most clinical protocols targeting 400 to 700 ng/dL to balance efficacy against erythrocytosis risk.

A 2017 meta-analysis published in JAMA Internal Medicine examined cardiovascular outcomes in testosterone-treated patients and found no statistically significant increase in major adverse cardiovascular events (MACE) in short-term trials, though longer-term cardiovascular safety data remain an active area of research see JAMA Network. Idaho prescribers should assess baseline hematocrit and cardiovascular risk factors before initiating therapy.

Can You Get AndroGel via Telehealth in Idaho?

Telehealth prescribing of AndroGel is legally permitted in Idaho in 2026. Idaho Code allows licensed providers to prescribe Schedule III controlled substances via synchronous audio-visual telehealth encounters, provided the prescriber is licensed in Idaho or meets the DEA's telemedicine registration requirements adopted in 2023. Pure audio-only encounters are not sufficient for a Schedule III controlled substance prescription under current federal rules; a video connection is required.

HealthRX connects Idaho patients with board-certified physicians who can evaluate symptoms, review lab results, and issue AndroGel or compounded testosterone gel prescriptions entirely online. The typical workflow is: order a testosterone lab panel through a local draw site (LabCorp and Quest both operate in Boise, Meridian, Nampa, Pocatello, and Idaho Falls), complete a video visit once results are in, then receive an electronic prescription sent directly to your preferred Idaho pharmacy or a mail-order compounding pharmacy licensed in Idaho.

Most telehealth TRT platforms complete the initial evaluation in 5 to 7 business days from lab draw to prescription. Follow-up testosterone monitoring is required at 6 to 8 weeks after starting or adjusting dose, then every 6 to 12 months once stable.

Comparing Your Options: A Side-by-Side Cost Summary

For an Idaho male patient paying cash in 2026, the monthly cost picture looks like this:

| Option | Estimated Monthly Cost | Notes | |---|---|---| | Branded AndroGel 1.62% (no discount) | $510 | AbbVie list price | | Branded AndroGel 1.62% (AbbVie copay card, commercially insured) | $0 to $30 | Card benefit caps apply | | Generic testosterone gel 1.62% (GoodRx at Walmart/Kroger) | $170 to $240 | Varies by Idaho pharmacy | | Compounded testosterone gel 1.62% (503A pharmacy) | ~$120 | Patient-specific Rx required | | Injectable testosterone cypionate (generic, cash) | $25 to $40 | Requires self-injection |

The compounded gel occupies the sweet spot for cash-pay Idaho patients who prefer a topical route over injections but cannot access the AbbVie card. Injectable testosterone cypionate remains the least expensive option by a wide margin for patients without a strong preference for gel delivery.

Transfer Risk and Skin Contact Safety in Idaho Households

One safety issue specific to gel formulations deserves attention regardless of cost. AndroGel and compounded testosterone gels can transfer to women and children through skin-to-skin contact. The FDA added a black-box warning to all topical testosterone products after reports of virilization in children who had incidental contact with treated skin see FDA label.

Idaho households with young children or female partners should apply gel only to covered areas (shoulders, upper arms per approved labeling), allow the application site to dry completely (3 to 5 minutes), wash hands after application, and cover the application site with clothing before contact with others. Covering the site substantially reduces but does not eliminate transfer risk. Partners who are pregnant or may become pregnant should avoid contact with treated skin entirely.

What to Bring to Your Idaho Prescriber Visit

Getting an AndroGel prescription, whether in-person in Boise or via telehealth, requires documented hypogonadism. Bring or upload the following before your appointment:

1. Two morning serum total testosterone results (drawn before 10 a.m. on separate days), both below 300 ng/dL.
2. A complete metabolic panel and CBC (hematocrit above 54% is a contraindication to starting testosterone therapy).
3. A list of current medications (5-alpha reductase inhibitors, opioids, and certain antifungals interact with testosterone metabolism).
4. PSA level if you are over 40, given that testosterone therapy is contraindicated in men with known or suspected prostate or breast cancer per FDA labeling.
5. Your insurance card and pharmacy preference so the prescriber can select the most cost-effective formulation from the outset.

The Endocrine Society guideline specifies a baseline PSA above 4 ng/mL as a reason to evaluate for prostate pathology before starting testosterone, and a PSA above 3 ng/mL in men at high risk of prostate cancer (African American men or men with a first-degree relative with prostate cancer before age 65) see Endocrine Society guideline.

What Happens If You Stop AndroGel Without a Plan

Abrupt discontinuation of testosterone gel after several months of therapy can produce a temporary hypogonadal state because exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. Endogenous testosterone production may take 3 to 6 months to recover, and in some patients with pre-existing primary hypogonadism, recovery is incomplete. Symptoms of withdrawal can include fatigue, low mood, and reduced libido in the weeks after stopping.

If cost is the reason for stopping, contact your prescriber before discontinuing. Switching to injectable testosterone cypionate at $25 to $40 per month or applying for the AbbVie PAP can eliminate the financial barrier without forcing an abrupt treatment gap. Recovery of the HPG axis is faster and more complete when dosing is tapered rather than stopped abruptly, though formal tapering protocols vary by practice.